

JOURNAL OF CLINICAL ONCOLOGY

OFFICIAL JOURNAL OF THE AMERICAN
SOCIETY OF CLINICAL ONCOLOGY

EDITOR-IN-CHIEF

Stephen A. Cannistra, MD

DEPUTY EDITOR

International Editions
David M. Khayat, MD, PhD

ASSOCIATE EDITORS

Judith Abrams, PhD
Karla V. Ballman, PhD
Michael A. Carducci, MD
Jonathan W. Friedberg, MD
Pamela J. Goodwin, MD
Bruce G. Haffty, MD
Melissa M. Hudson, MD
Paul B. Jacobsen, PhD
Stephanie R. Land, PhD
T. Andrew Lister, MD
Tony S.K. Mok, MD
Danny Rischin, MD
Joan H. Schiller, MD
Gary K. Schwartz, MD
Joel E. Tepper, MD
Alan P. Venook, MD
Jaap Verweij, MD, PhD
Antonio C. Wolff, MD

CONSULTANT EDITORS

Harold J. Burstein, MD, PhD
Medical Education

Levi Garraway, MD, PhD
Translational Oncology

Mark N. Levine, MD
Health Research Methodology

Lidia Schapira, MD
The Art of Oncology

PUBLISHER

David Sampson
T: 571-483-1708
F: 703-684-8720
david.sampson@asco.org

MANAGING EDITOR

Ken G. Kornfield
T: 703-797-1900
F: 703-684-8720
jco@asco.org

MANUSCRIPT SUBMISSION

<http://submit.jco.org>

CUSTOMER SERVICE

T: 703-519-1430 or
888-273-3508
F: 703-518-8155
jcoservice@asco.org

2318 Mill Road, Suite 800
Alexandria, VA 22314
www.jco.org
www.asco.org

Pieter Sonneveld, MD, PhD
Erasmus Medical Center
Dr Molewaterplein 40
Room L 407
Rotterdam, 3015 GD
Netherlands

December 19, 2014

Dear Dr. Sonneveld,

Please accept my sincere congratulations on being among *JCO*'s top-cited authors! According to data from Thomson Reuters provided to *JCO*, your article, "Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial" (*J Clin Oncol* 30: 2946-2955, 2012), was one of the most-cited articles published in 2012. Since publication, your article has been cited 134 times. Please be sure to inform your co-authors of this exciting news. Thank you for choosing to be a part of the *JCO* community and for helping to make *JCO* a leading journal in our field.

Our impact factor is one of the highest among oncology specialty journals. With a circulation of approximately 26,000 readers, and with features such as the Rapid Review program for selected papers, *JCO* attracts some of the most highly valued and prestigious clinical research in the world. Your paper is included among the best of this group.

Thank you for your continued support of *JCO*.

Sincerely yours,



Stephen A. Cannistra, MD
Editor-in-Chief
Journal of Clinical Oncology
JCO@asco.org